Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) cut its second-quarter 2026 net loss 39% to about $9.5 million, or $0.26 per share, from $15.7 million, or $0.52 per share, a year earlier. Operating expenses fell 16% to about $13.0 million, and the company reiterated its full-year revenue guidance of about $25.0 million.